To meet growing demand from the pharmaceutical industry, Asahi Kasei has established Asahi Kasei Life Science to operate its bioprocess businesses under a new organizational structure.
The Seqens Group, a global manufacturer of health, personal care, and specialty ingredients, recently announced a strategic partnership with Novonesis, a sustainable biological solutions provider.
Syngene, a global contract research, development, and manufacturing organization (CRDMO), recently announced the acquisition of its first biologics site in the USA – fitted with multiple monoclonal antibody (mAbs) manufacturing lines.
This Article Collection delves into the latest research and applications of adeno-associated viruses (AAVs), highlighting advancements in production, characterization, and purification processes.
Syensqo recently announced a strategic five-year partnership with Bota Bio, a global industrial biotechnology company specializing in biomanufactured, clean, and high-performance consumer products.
In a move to expand its global biomanufacturing network, US biopharma Amgen is planning to invest $1 billion to build a second drug substance manufacturing facility at its US site in Holy Springs, North Carolina. This brings the company's total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.
Samsung Biologics, a global contract development and manufacturing organization (CDMO), recently announced a series of manufacturing deals with a Europe-based pharmaceutical company.
Ambiopharm, a US-based pharmaceutical services company specializing in peptide manufacturing, recently announced the groundbreaking of a 70,000-square-foot (6,504 m2) capacity expansion project at its Shanghai manufacturing site. This $28 million (€26.6 million) project reflects the company’s commitment to serving growing global demand and confidence in China’s vital role in the global pharmaceutical supply chain.
Lonza, a global contract development and manufacturing organization (CDMO) for the pharmaceutical, biotech, and nutraceutical markets, announced today that it will invest in additional bioconjugation capabilities in Visp, Switzerland.
Sterling Pharma Solutions, a global contract development and manufacturing organization (CDMO), today announced the second phase of an expansion strategy at its Deeside, UK site to support antibody-drug conjugate (ADC) development, with a more than £10 million (€11.9 million) investment to increase GMP bioconjugation capacity.
Eli Lilly and Company (Lilly) recently announced a $4.5 billion (€4.07 billion) investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development.
Lonza and Vertex Pharmaceuticals recently announced a commercial supply agreement for casgevy (exagamglogene autotemcel).
The minicircle has emerged as a Next Generation Gene Vector and as a promising tool in the field of gene delivery and therapeutic applications. This overview aims to cover the characteristics, production methods, and potential applications of minicircle DNA.
Bill Humphries, CEO of Alcami, shares his vision for the future, discussing dynamic market trends and the company’s commitment to innovation. Under his leadership, Alcami is poised to redefine the pharmaceutical and biotechnology landscape, focusing on cutting-edge solutions and navigating global complexities. This conversation highlights Alcami’s strategic direction, accomplishments, and upcoming challenges.
Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and manufacturing organizations/contract manufacturing organizations (CDMOs/CMOs), including several multi-billion large-scale biomanufacturing projects. What companies are expanding, and where do these expansions stand?
Lonza recently announced that it has completed a planned expansion of the mid-scale microbial manufacturing facility at its Visp, Switzerland site. This multi-product facility was recently granted a GMP license, allowing cGMP manufacturing and release of biologics produced using microbial fermentation.
Major US drugmaker MSD is to pay up to $1.3 billion to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from biotechnology company Curon Biopharmaceutical.
This eBook provides scientists with more information on antibody–drug conjugates (ADCs), allowing you to further your research in this field.
Touchlight, a UK-based custom development and manufacturing organization (CDMO) specializing in enzymatic DNA production, signed a license agreement with British drugmaker GSK which grants GSK non-exclusive rights to use Touchlight’s proprietary enzymatic dbDNA (doggybone DNA) technology for the development and production of mRNA-based products.
Santa Clara, CA-based Agilent Technologies has signed a definitive agreement to acquire specialized contract development and manufacturing organization Biovectra from H.I.G. Capital in a move to expand its end-to-end biopharma solutions.
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform.
This article collection hopes to provide scientists with more information on biopharmaceutical analytics allowing you to further your research in biomanufacturing.
With the advent of advanced chromatographic methods, researchers can now delve into the intricacies of biological samples with unparalleled precision.
Kyowa Kirin announced a new, state-of-the-art manufacturing facility in Sanford, North Carolina, US. Kyowa Kirin will invest up to $530 million (€489 million) in constructing a 15,951m2 two-bioreactor facility, scheduled to break ground in Q3 of 2024.
Aurigene Pharmaceutical Services Limited (Aurigene), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 6500 m2 (70,000 sq ft) in Hyderabad, India.
Ori Biotech a cell and gene therapy (CGT) manufacturing technology producer, recently announced the commercial launch of IRO, a next-generation platform.
Enzene Biosciences, a global CDMO announces the launch of a new Drug Discovery Division.
On Monday, Paris-based French drugmaker Sanofi announced plans to invest more than €1 billion at three facilities in France to create new bioproduction capacity.
Life science group Sartorius and biopharmaceutical firm Sanofi are partnering to create a platform for continuous downstream bioprocessing. Sartorius will use its engineering and manufacturing skills to commercialize integrated and continuous biomanufacturing (ICB) platforms, using Sanofi’s prototypes. In exchange, Sanofi will provide Sartorius with exclusive access to its ICB platform knowledge and patents.
Download this complimentary Expert Insights eBook today!
This Expert Insights eBook is designed to enhance scientists’ understanding of qPCR for cell and gene therapy, enabling further research in the field of drug discovery and development.
Aragen, a CRDMO, has launched the first phase of its biologics manufacturing facility in Bangalore, India. The $30 million project, executed by its subsidiary Aragen Biologics Pvt Ltd, has completed its first small-scale manufacturing project for a US-based organization, producing a novel anticancer monoclonal antibody.
Greentech firm Afyren Neoxy, a subsidiary of Afyren, received a €3.4 million payment this week for achieving key milestones with its bio-based low-carbon products.
Evonik Vland Biotech, a new joint venture between Evonik China and Shandong Vland Biotech, began operations on January 1, 2024. The venture aims to expand the market presence of their livestock probiotics in Greater China and develop new products. The official opening took place in Qingdao on March 14.
Epsilogen and Lonza have successfully completed the manufacturing of a potential cancer treatment. The complex process, which took less than ten months, was carried out at Lonza’s UK site following Good Manufacturing Practice (GMP) standards.
